Lilly's Manufacturing Reorg Reflects Changing Diabetes Market Dynamics
This article was originally published in The Pink Sheet Daily
Executive Summary
Competition from Merck's DPP-4 inhibitor Januvia and progress made by Lilly's own Byetta alter firm's insulin market expectations.